The director and a core faculty member of the Johns Hopkins Berman Institute of Bioethics have been appointed co-chairs of an Institute of Medicine committee that will evaluate the scientific and ethical issues involved in studies of drug safety after FDA approval.
Ruth Faden, Ph.D., M.P.H., director of the Berman Institute of Bioethics, and Steven Goodman, M.D., Ph.D., in the Division of Biostatistics at the Johns Hopkins Kimmel Cancer Center and on faculty at the Berman Institute, will lead the 12-member Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs.
The group's immediate priority will be to deliver a brief report on July 1 outlining the ethical issues that must be considered when designing clinical trials to evaluate the safety of drugs after they are on the market.
"Rarely does the Institute of Medicine appoint two scholars from the same university to be committee co-chairs," Faden said. "I am honored to serve with Steve, and for the opportunity to make a contribution to this significant challenge to the nation's health."
Longer-term goals of the committee will be to evaluate the scientific and ethical merits of various approaches to generating evidence about the safety of drugs that are approved and marketed; to consider the cost, speed and value of those approaches; and to determine when head-to-head clinical trials for safety are appropriate.
The committee — sponsored by the Food and Drug Administration and comprising bioethicists and experts in drug safety, research methodology and public health — is expected to issue a final report by next spring.
An initial open session will be held in Washington, D.C., on Monday, June 7. Speaking at the event will be Margaret Hamburg, M.D., commissioner of the Food and Drug Administration; Francis Collins, M.D., Ph.D., director of the National Institutes of Health; and Carolyn Clancy, M.D., director of the Agency for Healthcare Research.
Food additive emulsifiers linked to increased risk of type 2 diabetes